Korean J Ophthalmol.  2017 Jun;31(3):240-248. 10.3341/kjo.2016.0026.

Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome

• Kim JM
• Kim JH
• Chang YS
• Kim JW
• Kim CG
• Lee DW

• KMID: 2379880
• DOI: http://doi.org/10.3341/kjo.2016.0026

Abstract

PURPOSE
To evaluate the 12-month outcome of intravitreal anti-vascular endothelial growth factor therapy in eyes with bilateral retinal angiomatous proliferation (RAP).
METHODS
This retrospective observational study included 38 eyes of 19 patients with stage 1 or 2 bilateral RAP at diagnosis. The eyes of patients who exhibited different baseline best-corrected visual acuity (BCVA) values in both eyes were assigned to one of two groups"”the better (n=13) and worse (n=13) visual acuity groups. The BCVA values in both groups were compared to those at baseline and at 12 months. In addition, the 12-month changes in BCVA were compared between the two groups. The association between the optical coherence tomography findings at diagnosis and the 12-month BCVA was also analyzed.
RESULTS
The values of mean baseline and 12-month BCVA in the better visual acuity group (13 eyes) were 0.48 ± 0.19 and 0.58 ± 0.29, respectively, and those in the worse visual acuity group (13 eyes) were 0.83 ± 0.20 and 0.90 ± 0.31. The 12-month changes in BCVA were not significantly different between the two groups (p=0.786). Among the six patients with equivalent baseline BCVA in both eyes, four patients (66.7%) exhibited 1 to 2 lines or ≥3 lines of difference in BCVA between eyes at 12 months. Eyes without pigment epithelial detachment (PED) at diagnosis exhibited significantly better BCVA at 12 months than eyes with PED (p=0.021).
CONCLUSIONS
Better baseline visual acuity was associated with better BCVA at 12 months posttreatment in patients with bilateral RAP. However, equivalent baseline visual acuity in both eyes might not guarantee similar treatment outcomes. In addition, the absence of PED is predictive of better visual outcome.

Keyword

Bevacizumab; Choroidal neovascularization; Macular degeneration; Ranibizumab; Retinal angiomatous proliferation

MeSH Terms

Bevacizumab
Choroidal Neovascularization
Diagnosis
Endothelial Growth Factors*
Humans
Macular Degeneration
Observational Study
Ranibizumab
Retinaldehyde*
Retrospective Studies
Tomography, Optical Coherence
Visual Acuity
Bevacizumab
Endothelial Growth Factors
Ranibizumab
Retinaldehyde

Figure

• 

  Fig. 1 A representative case showing treatment outcome of bilateral retinal angiomatous proliferation. At diagnosis (A-F), the visual acuities of the right and left eyes were 20 / 50 and 20 / 50, respectively (arrows in panels C and D indicate the retinal angiomatous proliferation lesion). The eyes were treated with anti-vascular endothelial growth factor for 12 months. At 12 months posttreatment (G-J), despite a mild recurrence of exudation in the left eye, the visual acuities of the right (G,I) and left (H,J) eyes had improved to 20 / 25 and 20 / 30, respectively. (A,B,G,H): Fundus photography images; (C,D): indocyanine green angiography images; (E,F,I,J): optical coherence tomography images.

• 

  Fig. 2 Scatterplot showing the association of baseline and 12-month logarithm of minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) values between the eyes of a pair. Positive values indicate better visual acuity of the right eye compared to that of the left eye, and negative values indicate better visual acuity of the left eye compared to that of the right eye.

• 

  Fig. 3 Results of best-corrected visual acuity (BCVA) evaluation in eyes with bilateral retinal angiomatous proliferation divided into subgroups according to the baseline VA. (A) Changes in BCVA in 13 patients exhibiting different BCVA values in both eyes at baseline. Closed circles (solid line) indicate eyes with better baseline VA, and closed squares (dashed line) indicate eyes with worse baseline VA. (B) Changes in the proportions of patients exhibiting the equivalent VA, 1 to 2 lines of difference in BCVA, and ≥3 lines of difference in BCVA in both eyes from baseline to 12 months posttreatment. These data were derived from six patients with equivalent baseline BCVA in both eyes. logMAR = logarithm of minimal angle of resolution.

• 

  Fig. 4 Results of best-corrected visual acuity (BCVA) evaluation in eyes with bilateral retinal angiomatous proliferation (RAP) divided into subgroups according to stage of disease. (A) Changes in BCVA in eight patients exhibiting different stages of RAP in paired eyes. Closed circles (solid line) indicate eyes with lower stage (stage 1) of disease, and closed squares (dashed line) indicate eyes with higher stage (stage 2) of disease. (B) Changes in the proportions of patients exhibiting equivalent visual acuity, 1 to 2 lines of difference in BCVA, and ≥3 lines of difference in BCVA in paired eyes from baseline to 12 months posttreatment. These data were derived from 11 patients with the same stage of RAP in paired eyes. logMAR = logarithm of minimal angle of resolution.

Reference

1. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001; 21:416–434.

2. Gross NE, Aizman A, Brucker A, et al. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina. 2005; 25:713–718.

3. Campa C, Harding SP, Pearce IA, et al. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye (Lond). 2010; 24:1585–1589.

4. Sawa M, Ueno C, Gomi F, Nishida K. Incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation. Retina. 2014; 34:761–767.

5. Chang YS, Kim JH, Yoo SJ, et al. Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population. Acta Ophthalmol. 2016; 94:e49–e53.

6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419–1431.

7. CATT Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364:1897–1908.

8. Kang S, Roh YJ. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol. 2009; 53:389–395.

9. Chang YS, Han JI, Yoo SJ, et al. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity. Korean J Ophthalmol. 2014; 28:466–472.

10. Lee SY, Kim JG, Joe SG, et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol. 2008; 22:92–99.

11. Hemeida TS, Keane PA, Dustin L, et al. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol. 2010; 94:701–705.

12. Gharbiya M, Parisi F, Cruciani F, et al. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen. Retina. 2014; 34:298–305.

13. Parodi MB, Iacono P, Menchini F, et al. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2013; 91:267–273.

14. Inoue M, Arakawa A, Yamane S, Kadonosono K. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. Br J Ophthalmol. 2014; 98:956–960.

15. Rouvas AA, Chatziralli IP, Theodossiadis PG, et al. Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation. Retina. 2012; 32:1181–1189.

16. Lai TY, Chan WM, Liu DT, Lam DS. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1877–1880.

17. Reche-Frutos J, Calvo-Gonzalez C, Perez-Trigo S, et al. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome. Eur J Ophthalmol. 2011; 21:783–788.

18. Konstantinidis L, Mameletzi E, Mantel I, et al. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol. 2009; 247:1165–1171.

19. Kang JH, Park KA, Chung SE, Kang SW. Retinal angiomatous proliferation and intravitreal bevacizumab injection. Korean J Ophthalmol. 2007; 21:213–215.

20. Cohen SY, Dubois L, Tadayoni R, et al. Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation. Br J Ophthalmol. 2007; 91:354–359.

21. Ueda-Arakawa N, Ooto S, Nakata I, et al. Prevalence and genomic association of reticular pseudodrusen in age-related macular degeneration. Am J Ophthalmol. 2013; 155:260–269.e2.

22. Kim JH, Chang YS, Kim JW, et al. Prevalence of subtypes of reticular pseudodrusen in newly diagnosed exudative age-related macular degeneration and polypoidal choroidal vasculopathy in Korean patients. Retina. 2015; 35:2604–2612.

23. Haas P, Esmaeelpour M, Ansari-Shahrezaei S, et al. Choroidal thickness in patients with reticular pseudodrusen using 3D 1060-nm OCT maps. Invest Ophthalmol Vis Sci. 2014; 55:2674–2681.

24. Ueda-Arakawa N, Ooto S, Ellabban AA, et al. Macular choroidal thickness and volume of eyes with reticular pseudodrusen using swept-source optical coherence tomography. Am J Ophthalmol. 2014; 157:994–1004.

25. Kang HM, Kwon HJ, Yi JH, et al. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol. 2014; 157:1013–1021.

26. Jonas JB, Tao Y, Rensch F. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity. J Ocul Pharmacol Ther. 2011; 27:401–405.

27. Matsumoto H, Sato T, Kishi S. Tomographic features of intraretinal neovascularization in retinal angiomatous proliferation. Retina. 2010; 30:425–430.

28. Rouvas AA, Papakostas TD, Ntouraki A, et al. Angiographic and OCT features of retinal angiomatous proliferation. Eye (Lond). 2010; 24:1633–1642.

29. Kim JH, Chang YS, Kim JW, et al. Diagnosis of type 3 neovascularization based on optical coherence tomography images. Retina. 2016; 36:1506–1515.

30. Kim JH, Kim JR, Kang SW, et al. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophthalmol. 2013; 155:743–749. 749.e1–749.e2.

31. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016; 50:1–24.

32. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143:566–583.